دورية أكاديمية
[Clinical and economic expedience of ertapenem therapy of complicated urinary tract infection].
| العنوان: | [Clinical and economic expedience of ertapenem therapy of complicated urinary tract infection]. |
|---|---|
| المؤلفون: | Kolbin AS, Sidorenko SV, Zagorodnikova KA, Musatov VB, Iakovlev AA |
| المصدر: | Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] [Antibiot Khimioter] 2011; Vol. 56 (1-2), pp. 35-42. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: Izdatelstvo Meditsina Country of Publication: Russia (Federation) NLM ID: 8803688 Publication Model: Print Cited Medium: Print ISSN: 0235-2990 (Print) Linking ISSN: 02352990 NLM ISO Abbreviation: Antibiot Khimioter Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Moskva : Izdatelstvo Meditsina Original Publication: Moskva : Meditsina, c1988- |
| مواضيع طبية MeSH: | Anti-Bacterial Agents/*administration & dosage , Anti-Bacterial Agents/*economics , Urinary Tract Infections/*drug therapy , Urinary Tract Infections/*economics , beta-Lactams/*administration & dosage , beta-Lactams/*economics, Anti-Bacterial Agents/pharmacokinetics ; Costs and Cost Analysis ; Drug Resistance, Bacterial/drug effects ; Ertapenem ; Female ; Gram-Negative Bacteria ; Humans ; Male ; Russia ; Urinary Tract Infections/microbiology ; beta-Lactams/pharmacokinetics |
| مستخلص: | Clinical and economic investigation of various antibiotics use in the treatment of complicated urinary tract infection (CUTI) was performed under the Russian economic environment. The drugs of comparison were ertapenem, ceftriaxone and levofloxacin. Direct costs and their structure were shown, and the cost efficiency was calculated. Alternative analysis and one-side susceptibility analysis were performed. In complicated urinary tract infections when the major pathogens were Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis it was clinically and economically reasonable to start the treatment with ceftriaxone or ertapenem, while levofloxacin could be an alternative strategy. When the effects of the acquired resistance on the treatment effectiveness were evaluated (SIS model) it was shown that the pathogens susceptibility to ertapenem was preserved for a significantly longer time than that to ceftriaxone or levofloxacin (60 months). Such a parameter may serve as an additional evidence of the reasonable use of ertapenem as the starting treatment of CUTI. |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (beta-Lactams) G32F6EID2H (Ertapenem) |
| تواريخ الأحداث: | Date Created: 20110726 Date Completed: 20110928 Latest Revision: 20181201 |
| رمز التحديث: | 20240628 |
| PMID: | 21780670 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0235-2990 |
|---|